Social Media Posts Misinterpret Biden on mRNA Cancer Vaccines factcheck.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from factcheck.org Daily Mail and Mail on Sunday newspapers.
Results from the 24-week extension period of the phase 2b ENLIVEN trial showed sustained improvements in liver fat, fibrosis, and inflammation among those treated with 30 mg weekly and 44 mg biweekly pegozafermin.
APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia
Foster City, CA, Hangzhou, CH, Gaithersburg, MD, Jan 07, 2021 - (ACN Newswire) - Apollomics, Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination- oncology therapies, and GlycoMimetics (Nasdaq: GLYC), today announced APL-106 (uproleselan) has been granted Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) for the treatment of relapsed/refractory acute myeloid leukemia (AML). This Breakthrough Therapy Designation for APL-106 reinforces its potential and is an important regulatory milestone for Apollomics as we prepare to initiate our clinical development work in China for patients suffering from AML, said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. AML is an aggressive disease and relapsed/refracto